Identifying amyloid pos CN with hypersynchronous phases at an early stage and suppressing that activity with a suitable medication (Bakker et al., 2015) could prevent this hypothesized interaction between amyloid and tau and thus eventually delay or even prevent the development of cognitive impairment. The gene discussed is MAPT; the disease is Cognitive impairment.